GB Jaissle, M Leitritz, F Gelisken, F … - Graefe's Archive for Clinical and Experimental …, 2009 - Springer Page 1. RETINAL DISORDERS One-year results after intravitreal bevacizumab therapy
for macular edema secondary to branch retinal vein occlusion ... Cited by 19 - Related articles - All 2 versions
EJ Chung, YT Hong, SC Lee, OW Kwon, HJ … - Graefe's Archive for Clinical and Experimental …, 2008 - Springer Abstract Purpose To evaluate the prognostic factors for visual outcome after
intravitreal bevacizumab injection to treat macular edema due to branch retinal
vein occlusion (BRVO). Methods Fifty eyes of 50 consecutive patients ... Cited by 12 - Related articles - All 3 versions
PV Algvere, A Kvanta, S Seregard - Acta ophthalmologica, 2008 - ncbi.nlm.nih.gov 1: Acta Ophthalmol. 2008 Jun;86(4):352-5. Shall we use Avastin or Lucentis for
ocular neovascularization? Algvere PV, Kvanta A, Seregard S. ... Cited by 3 - Related articles - BL Direct - All 2 versions
- ►prsjournal.com TA Ciulla, PJ Rosenfeld - Current Opinion in Ophthalmology, 2009 - journals.lww.com Recent findings: Early studies of the anti-VEGF agents, pegaptanib sodium,
ranibizumab, bevacizumab, VEGF trap, and bevasiranib in the treatment of various
neovascular diseases (eg, diabetic macular edema, retinal vein occlusion, ... Cited by 2 - Related articles - All 6 versions
WC Wu, KC Cheng, HJ Wu - Eye, 2009 - nature.com The mean follow-up was 282.73 70.62 days in the group administered with
triamcinolone acetonide and 253.92 36.10 days in the study group who accepted
bevacizumab, respectively. Visual acuity measurements improved ... Cited by 3 - Related articles - All 3 versions
- ►prsjournal.com A Sakamoto, A Tsujikawa, M Ota, N Yamaike, … - Clinical & Experimental Ophthalmology, 2009 - pt.wkhealth.com Methods:: Thirty-one eyes of 31 patients with MO associated with RVO were
examined and then treated with an intravitreal injection of bevacizumab. Of
these 31 eyes, 22 showed complete resolution of the MO at 1 month after ... Cited by 1 - Related articles - All 5 versions
JB Gunther, MM Altaweel - Survey of Ophthalmology, 2009 - Elsevier The use of intravitreal bevacizumab (Avastin) has greatly expanded since its
introduction into ophthalmic care 3 years ago. A PubMed search on 1 August 2008
revealed 51 ocular disease processes that have been treated with ... Cited by 3 - Related articles - All 23 versions
- ►duanessolution.com S Julien, P Heiduschka, S Hofmeister, U … - British Journal of Ophthalmology, 2008 - bjo.bmj.com Results: In the optic nerve, immunoreactivity for bevacizumab was most prominent
on day 1 after injection and diminished rapidly. In the blood vessels of the
nerve fibre layer, the staining was intense in the walls and weak in the ... Cited by 2 - Related articles - All 5 versions
LO HATTENBACH, F ARNDT… - RETINA, 2009 - journals.lww.com Early intervention aimed at restoration of blood flow could be critical for a
favorable outcome. Cur- rently, numerous surgical techniques with varying de-
grees of success are being advocated for the treatment of BRVO or ... Related articles - All 2 versions
